Factsheet for changes to item 73343 to enable testing for acalabrutinib

This page contains a factsheet on changes to MBS item 73343 from 1 September 2020.

Page last updated: 25 August 2020

From 1 September 2020, MBS item 73343 for 17p deletion testing by fluorescent in situ hybridisation (FISH) testing in patients with relapsed or refractory chronic lymphoid leukaemia (CLL) or small lymphocytic lymphoma (SLL), is changing to to enable testing to determine eligibility for acalabrutinib.

The below factsheet provides further guidance on this change.
PDF version Factsheet 73343 acalabrutinib (PDF 157 KB)
Word version Factsheet 73343 acalabrutinib (DOCX 89 KB)

In this section